Subconjunctival bevacizumab injection in treatment of recurrent p | 50673
Journal of Clinical and Experimental Ophthalmology

Journal of Clinical and Experimental Ophthalmology
Open Access

ISSN: 2155-9570

+44 1223 790975

Subconjunctival bevacizumab injection in treatment of recurrent pterygium

3rd International Conference on Clinical & Experimental Ophthalmology

April 15-17, 2013 Hilton Chicago/Northbrook, USA

Hussein Alhammami

AcceptedAbstracts: J Clin Exp Ophthalmol 2013

Abstract :

Objective: To determine the clinical effect of subconjunctival injection of bevacizumab in regression or halting growth in patients with recurrent pterygium. Method and materials: The study was an off-label; 2-dosing, interventional case series involving 20 patients with recurrent pterygium. They received subconjunctival bevacizumab (0.2ml/ 2.5mg). vascularity and thickness of Pterygium was graded. size of the pterygium (measured by surface area in cm2) was recorded from baseline to 6 months, after injection. Treatment-related complications and adverse events were reported. The main outcome of measurements was the change in grading, size, vascularity, thickness and color intensity. Results: 9 males (45%), 11 females (55%) of 20 patients were conducted in study with a mean age of 50.46 years�18.30 (rang 38-70). There was a significant reduction in grading with significant difference in the mean surface area of pterygium at different intervals (P < 0.05) and the size of pterygium was reduced. The reduction of color intensity was significant (P =0.031). No significant topical or systemic adverse reactions were recorded.

Biography :

Hussein Alhammami get fellowship of Iraqi commission of medical spcialization in 2006. He is Assistant Professor in ophthalmology department/ medical college/ Kufa University